NPS Pharmaceuticals and AstraZeneca are ending their six-year-old collaboration to develop new drugs for metabotropic glutamate receptors, or mGluRs. AstraZeneca is paying NPS $30 million for the full rights to the research. NPS says it will earmark these new funds for late-stage product development.
"This strategic move creates investment flexibility for NPS and enables us to use the monies from this deal, the previously announced Nycomed GATTEX deal and the approximately $10 million in savings over the next two years from this transaction to support the further development of our late-stage pipeline products, PREOS and GATTEX, in specialty indications," said NPS CEO Tony Coles.
- see the release on the breakup
ALSO: Just yesterday billionaire George Soros cut his investment in NPS to 1.8 percent. Report
Analyst puts NPS Pharma under microscope. Report
NPS sells drug rights. Report
NPS halves workforce in restructuring. Report
NPS sells two facilities. Report